// STATE LEGISLATION TRACKER

Louisiana HC R120: INSURANCE: Creates the PACE Task Force to prioritize access, care, and education on GLP-1 medications

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Passed

State: Louisiana
Bill: HC R120
Session: 2026
Filed: 2026-05-28
Read the bill: OpenStates →
Last reviewed: 2026-11-02

Plain-English Summary

This Louisiana bill creates a task force to study access, care, and education related to GLP-1 medications. The task force will evaluate the clinical history, availability, and insurance cost impact of these drugs and report its findings by February 2027. The bill does not directly address compounded peptides or other related policy areas.

Key Points

Task force to study GLP-1 medications.
Focus on access, care, and education.
Will evaluate insurance cost impact.
Report due by February 2027.

What to Watch For

Note Procedural note: Bill has passed the House and been sent to the Secretary of State, indicating it has moved through the legislative process for this session.

Where the Bill Stands

The bill has been adopted by the House and sent to the Secretary of State.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws